Answers are grounded in this paper and cite their sources.
The ACCESS study is a multicenter, randomized, double-blind, controlled Phase II clinical trial designed to rigorously evaluate the efficacy and safety of CTLA4Ig (abatacept) in combination with cyclophosphamide, compared to cyclophosphamide alone, for the treatment of lupus nephritis in individuals diagnosed with systemic lupus erythematosus (SLE).
No takes yet. Share an insight, caveat, or question.
Wofsy et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: